The impact of PD-L1 expression on clinical outcomes for patients with NPC who are receiving PD-1 inhibitors in combination with platinum-chemotherapy was assessed in the JUPITER-02 and RATIONALE-309 studies, with the former defining PD-L1 positivity as the presence of membrane staining of any intensity in 1% or greater of tumor cells or immune cells and the latter evaluating tumor positive score at a cut-off of 10% (high/low expression) [47,49]. This evidence concerns the gene CD274 and neoplasm.